Bio-Rad Laboratories Return on Tangible Equity 2010-2023 | BIO
Current and historical return on tangible equity values for Bio-Rad Laboratories (BIO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Bio-Rad Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $-0.64B | $8.01B | -7.86% |
| 2023-09-30 | $-0.16B | $7.70B | -1.91% |
| 2023-06-30 | $-0.43B | $7.71B | -5.13% |
| 2023-03-31 | $-0.19B | $9.03B | -2.25% |
| 2022-12-31 | $-3.63B | $8.88B | -42.01% |
| 2022-09-30 | $-6.02B | $7.73B | -62.16% |
| 2022-06-30 | $-1.93B | $8.34B | -16.82% |
| 2022-03-31 | $-0.09B | $9.59B | -0.74% |
| 2021-12-31 | $4.25B | $13.08B | 34.59% |
| 2021-09-30 | $6.67B | $14.86B | 58.61% |
| 2021-06-30 | $4.05B | $11.12B | 41.61% |
| 2021-03-31 | $4.11B | $10.13B | 47.33% |
| 2020-12-31 | $3.81B | $9.39B | 50.09% |
| 2020-09-30 | $3.52B | $8.33B | 53.30% |
| 2020-06-30 | $1.95B | $6.85B | 34.13% |
| 2020-03-31 | $1.58B | $5.89B | 29.96% |
| 2019-12-31 | $1.76B | $5.35B | 35.73% |
| 2019-09-30 | $0.38B | $4.72B | 8.35% |
| 2019-06-30 | $0.90B | $5.12B | 20.62% |
| 2019-03-31 | $0.57B | $4.49B | 13.98% |
| 2018-12-31 | $0.37B | $3.67B | 9.30% |
| 2018-09-30 | $1.28B | $4.25B | 35.75% |
| 2018-06-30 | $1.03B | $3.98B | 33.80% |
| 2018-03-31 | $0.77B | $3.81B | 29.78% |
| 2017-12-31 | $0.12B | $2.25B | 5.75% |
| 2017-09-30 | $0.02B | $2.15B | 0.78% |
| 2017-06-30 | $0.01B | $2.10B | 0.60% |
| 2017-03-31 | $0.03B | $2.00B | 1.28% |
| 2016-12-31 | $0.03B | $1.94B | 1.32% |
| 2016-09-30 | $0.09B | $1.98B | 5.06% |
| 2016-06-30 | $0.09B | $1.88B | 5.20% |
| 2016-03-31 | $0.10B | $1.79B | 5.99% |
| 2015-12-31 | $0.11B | $1.78B | 6.67% |
| 2015-09-30 | $0.10B | $1.70B | 6.59% |
| 2015-06-30 | $0.10B | $1.61B | 6.60% |
| 2015-03-31 | $0.10B | $1.45B | 7.10% |
| 2014-12-31 | $0.09B | $1.43B | 6.32% |
| 2014-09-30 | $0.08B | $1.39B | 5.71% |
| 2014-06-30 | $0.06B | $1.42B | 4.42% |
| 2014-03-31 | $0.07B | $1.46B | 4.74% |
| 2013-12-31 | $0.08B | $1.40B | 5.92% |
| 2013-09-30 | $0.09B | $1.33B | 7.10% |
| 2013-06-30 | $0.14B | $1.29B | 11.35% |
| 2013-03-31 | $0.15B | $1.24B | 12.77% |
| 2012-12-31 | $0.17B | $1.26B | 14.09% |
| 2012-09-30 | $0.18B | $1.18B | 16.40% |
| 2012-06-30 | $0.19B | $1.15B | 16.80% |
| 2012-03-31 | $0.18B | $1.10B | 16.12% |
| 2011-12-31 | $0.18B | $1.02B | 16.52% |
| 2011-09-30 | $0.19B | $1.14B | 17.43% |
| 2011-06-30 | $0.19B | $1.13B | 18.51% |
| 2011-03-31 | $0.18B | $1.05B | 20.10% |
| 2010-12-31 | $0.19B | $0.97B | 22.09% |
| 2010-09-30 | $0.16B | $0.87B | 19.86% |
| 2010-06-30 | $0.15B | $0.77B | 20.30% |
| 2010-03-31 | $0.15B | $0.75B | 21.61% |
| 2009-12-31 | $0.15B | $0.75B | 22.62% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $8.382B | $2.671B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $181.078B | 23.71 |
| Stryker (SYK) | United States | $127.496B | 30.54 |
| Medtronic (MDT) | Ireland | $114.087B | 16.15 |
| Boston Scientific (BSX) | United States | $109.519B | 34.88 |
| EssilorLuxottica (ESLOY) | France | $102.905B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.259B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.858B | 28.37 |
| ResMed (RMD) | United States | $32.110B | 30.15 |
| Koninklijke Philips (PHG) | Netherlands | $25.984B | 20.13 |
| Terumo (TRUMY) | Japan | $25.953B | 36.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.724B | 15.79 |
| Baxter (BAX) | United States | $17.963B | 12.77 |
| Insulet (PODD) | United States | $13.116B | 58.16 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.406B | 0.00 |
| Demant (WILYY) | Denmark | $10.234B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.488B | 35.22 |
| Lantheus Holdings (LNTH) | United States | $5.522B | 13.76 |
| Haemonetics (HAE) | United States | $4.862B | 24.05 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Perrigo (PRGO) | Ireland | $4.066B | 12.33 |
| Prestige Consumer Healthcare (PBH) | United States | $3.227B | 15.36 |
| Envista Holdings (NVST) | United States | $3.185B | 13.14 |
| Neogen (NEOG) | United States | $2.933B | 28.21 |
| QuidelOrtho (QDEL) | United States | $2.868B | 15.92 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.846B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.735B | 54.17 |
| TG Therapeutics (TGTX) | United States | $2.547B | 71.65 |
| ICU Medical (ICUI) | United States | $2.534B | 22.36 |
| Agios Pharmaceuticals (AGIO) | United States | $1.950B | 0.00 |
| Verano Holdings (VRNOF) | United States | $1.790B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.761B | 51.61 |
| Warby Parker (WRBY) | United States | $1.639B | 0.00 |
| InMode (INMD) | Israel | $1.550B | 8.24 |
| Owens & Minor (OMI) | United States | $1.424B | 12.41 |
| AdaptHealth (AHCO) | United States | $1.329B | 9.88 |
| National Vision Holdings (EYE) | United States | $1.240B | 39.45 |
| AtriCure (ATRC) | United States | $1.101B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.011B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.913B | 0.00 |
| Evolus (EOLS) | United States | $0.851B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.747B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.745B | 15.86 |
| Quanterix (QTRX) | United States | $0.664B | 0.00 |
| Valneva SE (VALN) | France | $0.618B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.612B | 14.39 |
| PetIQ (PETQ) | United States | $0.588B | 19.20 |
| TerrAscend (TSNDF) | Canada | $0.519B | 0.00 |
| Surmodics (SRDX) | United States | $0.494B | 30.91 |
| Jin Medical (ZJYL) | China | $0.465B | 0.00 |
| ZimVie (ZIMV) | United States | $0.464B | 39.58 |
| Aurora Cannabis (ACB) | Canada | $0.403B | 0.00 |
| Cerus (CERS) | United States | $0.364B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.364B | 11.71 |
| Biote (BTMD) | United States | $0.357B | 8.21 |
| Zynex (ZYXI) | United States | $0.346B | 47.30 |
| Viemed Healthcare (VMD) | United States | $0.276B | 27.35 |
| MacroGenics (MGNX) | United States | $0.273B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.264B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.263B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.246B | 15.49 |
| Organigram Holdings (OGI) | Canada | $0.209B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.209B | 0.00 |
| Omeros (OMER) | United States | $0.200B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.197B | 0.00 |
| Veru (VERU) | United States | $0.193B | 0.00 |
| High Tide (HITI) | Canada | $0.175B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.171B | 82.00 |
| InterCure (INCR) | Israel | $0.150B | 25.31 |
| Jushi Holdings (JUSHF) | United States | $0.138B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.134B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.128B | 18.14 |
| Cellectar Biosciences (CLRB) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 8.28 |
| MariMed (MRMD) | United States | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Brainsway (BWAY) | Israel | $0.090B | 0.00 |
| Chimerix (CMRX) | United States | $0.089B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.085B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.076B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.062B | 4.03 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.054B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| Bright Green (BGXX) | United States | $0.044B | 0.00 |
| United-Guardian (UG) | United States | $0.043B | 15.45 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Exagen (XGN) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.025B | 0.00 |
| Agape ATP (ATPC) | $0.020B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.014B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.003B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |